TEVA getting demolished, now down near 20 from its high of over 70 in 2015. I figured they'd probably have to cut their dividend eventually, considering the $35 billion in debt on the balance sheet from the big acquisition of Actavis last year. They paid a whopping $41 bil, and just as the generics landscape began to go south. Meanwhile Teva's proprietary Copaxone franchise lost its patent protection, so the company's profitability got hit from all sides.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.